Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Menomune®
Menomune: A, C, Y, W 135 Meningococcal Polysaccharide · 2 trials · 3 indications
Solicited Injection Site Reactions: Pain, Erythema, Swelling. Solicited Systemic Reactions: Fever (Temperature), Headache, Malaise, Myalgia. Grade 3 reactions were defined as: Pain, headache, malaise, and myalgia - significant, prevents daily activity; Erythema and swelling - \> 100 mm; Fever, temperature of ≥ 39.0ºC or ≥ 102.1ºF.
Solicited injection site reactions: pain, erythema, and swelling. Solicited systemic reactions: Fever (temperature), Headache, Malaise, Myalgia, chills, Arthralgia, Urticaria, Anorexia, Diarrhea, and Vomiting.
Solicited injection site reactions: Pain, Erythema, and Swelling.
Solicited systemic reactions: Fever (temperature), Headache, Malaise, Myalgia, chills, Arthralgia, Urticaria, Anorexia, Diarrhea, and Vomiting.
| Arm | Type | Description |
|---|---|---|
| Menomune® vaccine group | EXPERIMENTAL | Participants received Menomune® vaccine in MTA29 (NCT00874549) |
| Menactra® vaccine group | EXPERIMENTAL | Participants received Menactra® vaccine in trial MTA29 (NCT00874549) |
| Group 1: Menomune Day 0 | ACTIVE_COMPARATOR | Participants received a single dose of Menomune® vaccine on Day 0. |
| Group 2: Menactra® Day 0 x 2 | EXPERIMENTAL | Participants received two single-dose injections of Menactra® vaccine on Day 0 |
| Group 3: Menactra® Day 0 and 14 | EXPERIMENTAL | Participants received a single dose of Menactra® vaccine on Day 0 and on Day 14 |
| Group 4: Menactra® Day 0 and 28 | EXPERIMENTAL | Participants received a single dose of Menactra® vaccine on Day 0 and on Day 28. |
| Name | Type | Description |
|---|---|---|
| Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, Intramuscular |
| Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide | BIOLOGICAL | 0.5 mL, Subcutaneous |
| Menactra®: Polysaccharide Diphtheria Toxoid Conjugate | BIOLOGICAL | 0.5 mL, Intramuscular |
Inclusion Criteria: * Aged 56 years or older on the day of inclusion. * Received the appropriate Menactra or Menomune vaccine as assigned by randomization in Trial MTA29. * Ambulatory and healthy, as determined by medical history. * Informed consent form has been signed and dated. * Able to attend ...
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is a biologic vaccine developed by Sanofi for meningitis and meningococcal infections. It is a polysaccharide vaccine covering serogroups A, C, Y, and W-135, and it has been studied in older adults, including healthy volunteers aged 56 years and above.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is used for the prevention of meningitis and meningococcal infections. Its clinical studies enrolled healthy volunteers aged 56 years and older in the United States, evaluating safety and immune response against meningococcal disease in that age group.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is made by Sanofi, which trades under the ticker SNY. Sanofi is the developer associated with the vaccine, and the clinical trials of Menomune were sponsored and conducted under the Sanofi organization.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is in Phase 2 development. Its recorded clinical program includes one completed Phase 2 trial and one completed Phase 1/Phase 2 trial, and no trials are currently active. The vaccine remains an investigational asset in Sanofi's clinical development record.
Menomune: A, C, Y, W-135 Meningococcal Polysaccharide has been studied in two completed trials: NCT01239043, a Phase 2 trial of antibody persistence and response to revaccination with Menactra or Menomune three years after initial vaccination, and NCT00874549, a Phase 1/Phase 2 safety and immunogenicity trial in subjects aged 56 years and older.
Yes. Menomune: A, C, Y, W-135 Meningococcal Polysaccharide is the same product referred to as Menomune, including the variants Menomune: A, C, Y, W 135 Meningococcal Polysaccharide and Menomune: A, C, Y, W-135 Meningococcal Polysaccharide. These names all refer to the same Sanofi meningococcal polysaccharide vaccine.